Tag Archives: Tesaro

December, 2018

  • 5 December

    GlaxoSmithKline to Acquire Cancer Biotech Tesaro for $5.1 Billion

    LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction …

October, 2017

  • 27 October

    Evotec and Tesaro Partner to Discover Novel Immuno-Oncology Agents

    HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. Under the terms of the collaboration, Evotec will apply its integrated drug …

March, 2017

January, 2017

  • 13 January

    FDA Denies Approval of Tesaro’s NDA for its Rolapitant IV

    WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the rolapitant IV New Drug Application (NDA) for the prevention of delayed nausea and vomiting associated with …

December, 2016

  • 20 December

    Tesaro Announces Priority Review Designation for Niraparib NDA

    WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the niraparib New Drug Application (NDA). Niraparib is a PARP inhibitor that is being evaluated as a potential new treatment …

September, 2016

  • 14 September

    Tesaro’s Niraparib Receives Fast Track Designation from the FDA

    WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to niraparib for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. TESARO has initiated …

June, 2016

April, 2016

March, 2016

  • 30 March

    Tesaro and MD Anderson Enter Immuno-Oncology Collaboration

    WALTHAM, Mass. and HOUSTON, March 29, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets. …

February, 2016